Cargando…

Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China

BACKGROUND: Although pembrolizumab is recommended as a first-line treatment for advanced recurrent/unresectable/metastatic (R/U/M) head and neck squamous carcinoma, the differences in its efficacy among different populations need to be investigated. METHODS: We reviewed 15 consecutive patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jieying, He, Zongxuan, Tao, Yueqin, Yang, Xiaochen, Ge, Shengyou, Xu, Haoyue, Shang, Wei, Song, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229243/ https://www.ncbi.nlm.nih.gov/pubmed/37261276 http://dx.doi.org/10.1155/2022/7283946

Ejemplares similares

Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
por: Grob, Jean-Jacques, et al.
Publicado: (2020)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer
por: Wookey, Vanessa, et al.
Publicado: (2021)

Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population
por: Chen, Wen-Chun, et al.
Publicado: (2017)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Single‐Center Experience with Ifosfamide Monotherapy as Second‐Line Treatment of Recurrent/Metastatic Osteosarcoma
por: Verschoor, Arie Jan, et al.
Publicado: (2019)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study
por: Shimizu, Takuto, et al.
Publicado: (2022)

Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629
por: Bratland, Åse, et al.
Publicado: (2023)

Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041)
por: Choi, Min Chul, et al.
Publicado: (2020)

Phase I/II study of streptozocin monotherapy in Japanese patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors
por: Komoto, Izumi, et al.
Publicado: (2022)

A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma
por: Yeku, Oladapo, et al.
Publicado: (2020)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629
por: Hughes, Brett G. M., et al.
Publicado: (2021)

Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
por: Wurcel, Victoria, et al.
Publicado: (2021)

Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study
por: Kaakour, Dalia, et al.
Publicado: (2022)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
por: McCusker, Michael G, et al.
Publicado: (2020)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
por: Alam, Walid, et al.
Publicado: (2021)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab
por: Acero Brand, Fanny Zulay, et al.
Publicado: (2018)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab
por: Hober, Candice, et al.
Publicado: (2021)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States
por: Liu, Maobai, et al.
Publicado: (2019)

Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report
por: Muralikrishnan, Sivraj, et al.
Publicado: (2020)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence
por: Subramanian, Sundaram, et al.
Publicado: (2018)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
por: Kao, Hsiang-Fong, et al.
Publicado: (2022)

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
por: Harrington, Kevin J., et al.
Publicado: (2023)

Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome
por: Tos, Salem M., et al.
Publicado: (2022)

Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer
por: Alshamsan, Bader, et al.
Publicado: (2022)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k0efopdv0u3vbeq62ggc7rtpfm